| 前收市價 | 8.05 |
| 開市 | 8.05 |
| 買盤 | 5.00 |
| 賣出價 | 8.30 |
| 拍板 | 340.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 8.05 - 8.05 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 13 |
- Reuters
McKesson misses quarterly estimates as US pharmaceuticals segment weighs
McKesson Corp reported weaker-than-expected quarterly revenue and profit on Tuesday due to slump in demand for the company's branded and specialty drugs that dragged sales in its U.S. pharmaceutical segment. The segment also sells branded and generic drugs, as well as over-the-counter products and vaccines. Sales in the segment rose 11.5% in the fourth quarter to $68.79 billion, but missed analysts' estimate of $71.65 billion, according to LSEG data.
ZacksMcKesson (MCK) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksMcKesson (MCK) Q4 Earnings and Revenues Lag Estimates
McKesson (MCK) delivered earnings and revenue surprises of -2.52% and 3%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
